Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Daniel J. Booser"'
Autor:
Ricardo H. Alvarez, Daniel J. Booser, Abigail S. Caudle, JM Reuben, Kimberly B. Koenig, A Cyriac, Mariana Chavez-MacGregor, J. Schwartz Gomez, Joe Ensor, Jennifer K. Litton, V. Valero, Savitri Krishnamurty, Nuhad K. Ibrahim, Simona F. Shaitelman, Gary J. Whitman
Publikováno v:
Cancer Research. 76:P1-14
Background: Neoadjuvant chemotherapy (NACT) is an integral component for locally advanced and large operable breast cancer. The sequence of taxanes followed by anthracyclines has been the standard of care for almost 20 years. Eribulin (E) is a synthe
Autor:
Gabriela Sanchez Petitto, Jose Banchs, Raymundo Quintana Quezada, Adrian daSilva-deAbreu, Astrid Serauto, Daniel J. Booser
Publikováno v:
Journal of the American College of Cardiology. 71:A1523
Several oncologic and cardiovascular organizations have recommended routine left ventricular ejection fraction (LVEF) evaluation for all patients prior to anthracycline chemotherapy for breast cancer. Nevertheless, there is no clinical or cost-effect
Autor:
Henry L. Gomez, Daniel J. Booser, Vicente Valero, Keith Anderson, Lajos Pusztai, Richard L. Theriault, Peter J. Dempsey, Aman U. Buzdar, Roman Rouzier, Nuhad K. Ibrahim, Gabriel N. Hortobagyi, Tatiana Vidaurre, Jeffrey S. Ross, Nour Sneige, Kenneth R. Hess, Jaime A. Mejia, W. Fraser Symmans
Publikováno v:
Journal of Clinical Oncology. 24:4236-4244
Purpose We developed a multigene predictor of pathologic complete response (pCR) to preoperative weekly paclitaxel and fluorouracil-doxorubicin-cyclophosphamide (T/FAC) chemotherapy and assessed its predictive accuracy on independent cases. Patients
Autor:
Francisco J. Esteva, Terry L. Smith, W. Fraser Symmans, Edgardo Rivera, Gabriel N. Hortobagyi, W. Joseph Thompson, Lajos Pusztai, James L. Murray, Kimberly M. Nealy, Vicente Valero, Jim Hou Zhen, Banu Arun, Daniel J. Booser, Amy Gibbs, Clark M. Whitehead
Publikováno v:
Journal of Clinical Oncology. 21:3454-3461
Purpose: We studied the safety and clinical activity of exisulind in combination with capecitabine in 35 patients with metastatic breast cancer (MBC). Patients and Methods: All patients had received previous anthracycline and taxane chemotherapies. T
Autor:
Thorunn Helgason, Filip Janku, Vicente Valero, K. Koenig, Razelle Kurzrock, Vivek Subbiah, Jennifer J. Wheler, Jennifer K. Litton, David S. Hong, Nuhad K. Ibrahim, R. Basho, Daniel D. Karp, M. Gilcrease, Stacy L. Moulder, James L. Murray, Funda Meric-Bernstam, Daniel J. Booser, Constance Albarracin, Mariana Chavez-MacGregor
Publikováno v:
European Journal of Cancer. 51:S289-S290
Autor:
Francisco J. Esteva, Laura Guerra, Rebecca Arbuckle, Ebrahim S. Delpassand, Edgardo Rivera, M. Amir Ahmadi, Daniel J. Booser, Vicente Valero, Gabriel N. Hortobagyi, Bita Esmaeli
Publikováno v:
Ophthalmology. 109:1188-1191
Purpose To compare the frequency of canalicular stenosis as a side effect of weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer. Design Retrospective nonrandomized comparative trial. Patients and methods Eighteen patients
Autor:
Debra Frye, Marguerite Rosales, Massimo Cristofanilli, Edgardo Rivera, Daniel J. Booser, Vicente Valero, Gabriel N. Hortobagyi
Publikováno v:
Cancer. 94:2321-2326
PURPOSE The authors conducted a single-institution Phase I clinical trial to determine the maximum tolerated doses and to define the toxic effects of oral eniluracil and oral 5-fluorouracil (5-FU) combined with docetaxel in patients with metastatic b
Autor:
Francisco J. Esteva, Vicente Valero, Gabriel N. Hortobagyi, Edgardo Rivera, Z. Rahman, Massimo Cristofanilli, Laura Syrewicz, Daniel J. Booser
Publikováno v:
Cancer Chemotherapy and Pharmacology. 49:299-302
Purpose: We conducted a single-institution phase II clinical trial to determine the objective response rate, duration of response, time to progression, and overall survival in patients with anthracycline-resistant breast cancer treated with Doxil. Pa
Autor:
Francisco J. Esteva, Massimo Cristofanilli, Laura Guerra, Daniel J. Booser, Terry L. Smith, Herbert A. Fritsche, Gabriel N. Hortobagyi, James L. Murray, Nour Sneige, Banu Arun, Vicente Valero, Lajos Pusztai, Bita Esmaeli
Publikováno v:
Journal of Clinical Oncology. 20:1800-1808
PURPOSE: To evaluate the safety and efficacy of weekly docetaxel plus trastuzumab in women with HER-2–overexpressing metastatic breast cancer. Efficacy was correlated with serum HER-2 extracellular domain (ECD) levels. PATIENTS AND METHODS: Thirty
Autor:
Lan Ni, Richard Theriault, Maureen A. Major, Kapil Dhingra, Andrew D. Seidman, Pamela N. Munster, Larry Norton, Clifford A. Hudis, Daniel J. Booser, Aman U. Buzdar, Allen S. Melemed, Nathan H. Enas
Publikováno v:
Memorial Sloan Kettering Cancer Center
PURPOSE: We conducted this phase I trial to determine the safety and toxicity profile of LY353381.HCl—a novel, potent, third-generation selective estrogen receptor modulator (SERM)—because this benzothiophene derivative demonstrated an SERM profi